A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects
Latest Information Update: 08 Dec 2023
At a glance
- Drugs JS 010 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
Most Recent Events
- 08 Dec 2023 New trial record